NCT05254236撤回2 期
A Phase IIb, Randomized, Double-Blinded Trial to Evaluate the Immunogenicity and Safety Study of the Booster Dose Using the High or Medium Dose of COVID- 19 Vaccine (Vero Cell), Inactivated in Healthy Adults Who Have Completed Two Doses of mRNA Vaccine in Hong Kong
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Immunogenicity index-Geometric mean fold rise (GMFR) of neutralization antibody titre in the medium dose
研究概览
简要总结
This is a randomized, double-blinded, Phase IIb clinical trial of COVID-19 vaccine (CoronaVac®) manufactured by Sinovac Research & Development Co., Ltd.The purpose of this study is to evaluate to evaluate the changes in immunogenicity before and after the booster vaccine using the high (1200 SU) or medium (600 SU) dose of COVID-19 Vaccine (Vero Cell), Inactivated.
详细描述
This is a randomized, double-blinded, Phase IIb clinical trial of 150 participants aged 18 years and above, who have completed two doses of mRNA COVID-19 vaccine as the primary vaccination for at least six months after the second dose. After enrollment, participants will be randomly assigned into two study arms at a ratio of 1:1 to receive a booster of one dose of medium-dose (600 SU) or one dose of high-dose (1200 SU) COVID-19 Vaccine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adults aged 18 years and above, who have received two prior doses of mRNA COVID-19 vaccine (Comirnaty®, made by BioNTech/Pfizer) as the primary vaccination, with the second dose given at least 180 days prior to the day of booster vaccination in the present study;
- •Evidence of a deep throat saliva (DTS) PCR negative for SARS-COV-2 within 24 hours before enrollment;
- •Female participants who have a negative pregnancy test on the day of vaccination, and not currently breastfeeding;
- •The participants are able to understand and sign the informed consent voluntarily;
- •The participants are willing and able to comply with all schedule visits, sample collection,vaccine plan, and other study procedures;
- •The participants must be willing to provide verifiable identification (in accordance with the local regulations), has means to be contacted and to contact the investigator during the study.
排除标准
- •History of confirmed or having evidence showing a current infection of SARS-CoV-2 prior to randomization;
- •Any prior administration of another investigational coronavirus vaccine or current/planned simultaneous participation in another interventional study to prevent or treat COVID-19;
- •Known allergy to vaccines or vaccine ingredients, and serious adverse reactions to vaccines, such as urticaria, dyspnea, angioneurotic edema;
- •Serious chronic disease, serious cardiovascular disease, hypertension and diabetes that cannot be controlled by drugs, hepatorenal disease, malignant tumor, etc.;
- •Acute central nervous system diseases such as encephalitis/myelitis, acute disseminating encephalomyelitis, and related disorders;
- •Receipt of blood/plasma products or immunoglobulins in the past three months before vaccination in this study;
- •Participation in other studies involving study intervention within 30 days prior to vaccination in this study;
- •Receipt of attenuated live vaccines in the past fourteen days prior to vaccination in this study;
- •Receipt of inactivated or subunit vaccines in the past seven days prior to vaccination in this study;
- •Acute exacerbation or presentation of stable chronic diseases (including but not limited to asthma,migraine, gastrointestinal disorder, etc.);
- •Acute febrile illness with oral temperature >37.5C on the day of vaccination;
- •According to the investigator's judgment, the participant has any other factors that might interfere with the results of the clinical trial or pose additional risk to the participant due to participation in the study.
结局指标
主要结局
Immunogenicity index-Geometric mean fold rise (GMFR) of neutralization antibody titre in the medium dose
时间窗: 28 days after the booster dose vaccination
Geometric mean fold rise (GMFR) of neutralization antibody titre from baseline to 28 days post the booster vaccine in the medium dose .
Immunogenicity index-Geometric mean fold rise (GMFR) of neutralization antibody titre in the high dose
时间窗: 28 days after the booster dose vaccination
Geometric mean fold rise (GMFR) of neutralization antibody titre from baseline to 28 days post the booster vaccine in the high dose .
次要结局
- Immunogenicity index-GMT of neutralizing antibody in the high dose(3 months after the booster dose vaccination)
- Immunogenicity index-Geometric mean of neutralizing antibody titer (GMT)in the medium dose(28 days after the booster dose vaccination)
- Immunogenicity index-GMT of neutralizing antibody in the medium dose(3 months after the booster dose vaccination)
- Safety index-Occurrence and relationship of SAEs(Within 12 months post booster vaccination)
- Immunogenicity index-The seropositivity rate of neutralizing antibody in the medium dose(3 months after the booster dose vaccination)
- Immunogenicity index-the GMT of neutralizing antibody in the high dose(6 months after the booster dose vaccination)
- Immunogenicity index-the seropositivity rate of neutralizing antibody in the high dose(28 days after the booster dose vaccination)
- Immunogenicity index-The seropositivity rate of neutralizing antibody in the high dose(3 months after the booster dose vaccination)
- Immunogenicity index-The seropositivity rate in the high dose(6 months after the booster dose vaccination)
- Immunogenicity index-The seropositivity rate in the medium dose(6 months after the booster dose vaccination)
- Safety index-Occurrence and relationship of AESI(Within 12 months post booster vaccination)
- Immunogenicity index-the seropositivity rate of neutralizing antibody in the medium dose(28 days after the booster dose vaccination)
- Immunogenicity index-Geometric mean of neutralizing antibody titer (GMT) in the medium dose(28 days after the booster dose vaccination)
- Immunogenicity index-the GMT of neutralizing antibody in the medium dose(6 months after the booster dose vaccination)
- Safety index-Occurrence, intensity, duration, and relationship of solicited local and systemic AEs(28 days after the booster dose vaccination)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19COVID-19NCT05007496Aivita Biomedical, Inc.145
暂停
2 期
Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in TurkeyCOVID-19NCT05150496Sinovac Research and Development Co., Ltd.640
Unknown
4 期
Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19COVID-19NCT05079217Sinovac Biotech Co., Ltd1,200
已完成
4 期
Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19COVID-19NCT05165966Sinovac Life Sciences Co., Ltd.340
进行中（未招募）
4 期
Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 YearsCOVID-19NCT05112913Sinovac Research and Development Co., Ltd.2,520